This company has been marked as potentially delisted and may not be actively trading.

Deciphera Pharmaceuticals (DCPH) Competitors

DCPH vs. ABVX, PCVX, NUVL, KRYS, and CYTK

Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Abivax (ABVX), Vaxcyte (PCVX), Nuvalent (NUVL), Krystal Biotech (KRYS), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.

How does Deciphera Pharmaceuticals compare to Abivax?

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

: Deciphera Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Deciphera Pharmaceuticals $174.91M 12.65 -$194.94M -$2.21 N/A
Abivax N/A N/A -$380.27M -$5.37 N/A
: Abivax has a net margin of 0.00% compared to Deciphera Pharmaceuticals' net margin of -108.86%. Deciphera Pharmaceuticals' return on equity of -52.42% beat Abivax's return on equity.
Company Net Margins Return on Equity Return on Assets
Deciphera Pharmaceuticals -108.86% -52.42% -40.05%
Abivax N/A -146.43% -88.69%
: In the previous week, Abivax had 7 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 7 mentions for Abivax and 0 mentions for Deciphera Pharmaceuticals. Abivax's average media sentiment score of 1.45 beat Deciphera Pharmaceuticals' score of 0.00 indicating that Abivax is being referred to more favorably in the news media.
Company Overall Sentiment
Deciphera Pharmaceuticals Neutral
Abivax Positive
: Abivax has a consensus target price of $137.15, suggesting a potential upside of 12.25%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than Deciphera Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Deciphera Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Abivax
1 Sell rating(s)

0 Hold rating(s)

13 Buy rating(s)

1 Strong Buy rating(s)
2.93
: Deciphera Pharmaceuticals has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Abivax has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
: 71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 4.7% of Deciphera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Deciphera Pharmaceuticals	$174.91M	12.65	-$194.94M	-$2.21	N/A
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A

Company	Net Margins	Return on Equity	Return on Assets
Deciphera Pharmaceuticals	-108.86%	-52.42%	-40.05%
Abivax	N/A	-146.43%	-88.69%

Company	Overall Sentiment
Deciphera Pharmaceuticals	Neutral
Abivax	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Deciphera Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Deciphera Pharmaceuticals and Abivax tied by winning 8 of the 16 factors compared between the two stocks.

How does Deciphera Pharmaceuticals compare to Vaxcyte?

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

: In the previous week, Vaxcyte had 9 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 9 mentions for Vaxcyte and 0 mentions for Deciphera Pharmaceuticals. Vaxcyte's average media sentiment score of 0.94 beat Deciphera Pharmaceuticals' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media.
Company Overall Sentiment
Deciphera Pharmaceuticals Neutral
Vaxcyte Positive
: Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 56.29%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Deciphera Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Deciphera Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Vaxcyte
1 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.63
: 71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 4.7% of Deciphera Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Deciphera Pharmaceuticals has higher revenue and earnings than Vaxcyte. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Deciphera Pharmaceuticals $174.91M 12.65 -$194.94M -$2.21 N/A
Vaxcyte N/A N/A -$766.63M -$5.62 N/A
: Vaxcyte has a net margin of 0.00% compared to Deciphera Pharmaceuticals' net margin of -108.86%. Vaxcyte's return on equity of -25.88% beat Deciphera Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Deciphera Pharmaceuticals -108.86% -52.42% -40.05%
Vaxcyte N/A -25.88% -23.85%
: Deciphera Pharmaceuticals has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.

Company	Overall Sentiment
Deciphera Pharmaceuticals	Neutral
Vaxcyte	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Deciphera Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Deciphera Pharmaceuticals	$174.91M	12.65	-$194.94M	-$2.21	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$5.62	N/A

Company	Net Margins	Return on Equity	Return on Assets
Deciphera Pharmaceuticals	-108.86%	-52.42%	-40.05%
Vaxcyte	N/A	-25.88%	-23.85%

Summary

Vaxcyte beats Deciphera Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Deciphera Pharmaceuticals compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

: In the previous week, Nuvalent had 10 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 10 mentions for Nuvalent and 0 mentions for Deciphera Pharmaceuticals. Nuvalent's average media sentiment score of 0.56 beat Deciphera Pharmaceuticals' score of 0.00 indicating that Nuvalent is being referred to more favorably in the media.
Company Overall Sentiment
Nuvalent Positive
Deciphera Pharmaceuticals Neutral
: Nuvalent currently has a consensus target price of $137.25, suggesting a potential upside of 36.18%. Given Nuvalent's stronger consensus rating and higher probable upside, analysts plainly believe Nuvalent is more favorable than Deciphera Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvalent
1 Sell rating(s)
0 Hold rating(s)

16 Buy rating(s)

0 Strong Buy rating(s)
2.88
Deciphera Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 97.3% of Nuvalent shares are held by institutional investors. Comparatively, 71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. 10.2% of Nuvalent shares are held by insiders. Comparatively, 4.7% of Deciphera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Deciphera Pharmaceuticals has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nuvalent N/A N/A -$425.38M -$5.85 N/A
Deciphera Pharmaceuticals $174.91M 12.65 -$194.94M -$2.21 N/A
: Nuvalent has a net margin of 0.00% compared to Deciphera Pharmaceuticals' net margin of -108.86%. Nuvalent's return on equity of -39.29% beat Deciphera Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Nuvalent N/A -39.29% -35.01%
Deciphera Pharmaceuticals -108.86% -52.42% -40.05%
: Nuvalent has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.

Company	Overall Sentiment
Nuvalent	Positive
Deciphera Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88
Deciphera Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$5.85	N/A
Deciphera Pharmaceuticals	$174.91M	12.65	-$194.94M	-$2.21	N/A

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-39.29%	-35.01%
Deciphera Pharmaceuticals	-108.86%	-52.42%	-40.05%

Summary

Nuvalent beats Deciphera Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Deciphera Pharmaceuticals compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

: Krystal Biotech has a net margin of 52.64% compared to Deciphera Pharmaceuticals' net margin of -108.86%. Krystal Biotech's return on equity of 18.69% beat Deciphera Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Krystal Biotech 52.64% 18.69% 17.12%
Deciphera Pharmaceuticals -108.86% -52.42% -40.05%
: In the previous week, Krystal Biotech had 22 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 22 mentions for Krystal Biotech and 0 mentions for Deciphera Pharmaceuticals. Krystal Biotech's average media sentiment score of 0.69 beat Deciphera Pharmaceuticals' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the media.
Company Overall Sentiment
Krystal Biotech Positive
Deciphera Pharmaceuticals Neutral
: Krystal Biotech currently has a consensus target price of $324.11, suggesting a potential upside of 14.04%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Deciphera Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
0 Sell rating(s)
2 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.83
Deciphera Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Krystal Biotech has higher revenue and earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Krystal Biotech $389.13M 21.50 $204.83M $6.85 41.49
Deciphera Pharmaceuticals $174.91M 12.65 -$194.94M -$2.21 N/A
: 86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 4.7% of Deciphera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Krystal Biotech has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	52.64%	18.69%	17.12%
Deciphera Pharmaceuticals	-108.86%	-52.42%	-40.05%

Company	Overall Sentiment
Krystal Biotech	Positive
Deciphera Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Deciphera Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	21.50	$204.83M	$6.85	41.49
Deciphera Pharmaceuticals	$174.91M	12.65	-$194.94M	-$2.21	N/A

Summary

Krystal Biotech beats Deciphera Pharmaceuticals on 16 of the 16 factors compared between the two stocks.

How does Deciphera Pharmaceuticals compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

: Deciphera Pharmaceuticals has a net margin of -108.86% compared to Cytokinetics' net margin of -891.60%. Cytokinetics' return on equity of 0.00% beat Deciphera Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Cytokinetics -891.60% N/A -49.62%
Deciphera Pharmaceuticals -108.86% -52.42% -40.05%
: In the previous week, Cytokinetics had 25 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 25 mentions for Cytokinetics and 0 mentions for Deciphera Pharmaceuticals. Cytokinetics' average media sentiment score of 0.49 beat Deciphera Pharmaceuticals' score of 0.00 indicating that Cytokinetics is being referred to more favorably in the media.
Company Overall Sentiment
Cytokinetics Neutral
Deciphera Pharmaceuticals Neutral
: Cytokinetics currently has a consensus target price of $91.25, indicating a potential upside of 17.91%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cytokinetics is more favorable than Deciphera Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytokinetics
1 Sell rating(s)
3 Hold rating(s)

17 Buy rating(s)

1 Strong Buy rating(s)
2.82
Deciphera Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Deciphera Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytokinetics $88.04M 109.21 -$784.96M -$6.53 N/A
Deciphera Pharmaceuticals $174.91M 12.65 -$194.94M -$2.21 N/A
: 71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 4.7% of Deciphera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Cytokinetics has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-891.60%	N/A	-49.62%
Deciphera Pharmaceuticals	-108.86%	-52.42%	-40.05%

Company	Overall Sentiment
Cytokinetics	Neutral
Deciphera Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
Deciphera Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	109.21	-$784.96M	-$6.53	N/A
Deciphera Pharmaceuticals	$174.91M	12.65	-$194.94M	-$2.21	N/A

Summary

Cytokinetics beats Deciphera Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Deciphera Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCPH vs. The Competition

Export

Metric	Deciphera Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.21B	$886.50M	$6.24B	$11.87B
Dividend Yield	N/A	4.84%	2.73%	5.21%
P/E Ratio	-11.58	1.71	29.06	28.45
Price / Sales	12.65	119.94	475.43	61.47
Price / Cash	N/A	20.07	27.62	36.52
Price / Book	5.84	7.59	9.69	6.64
Net Income	-$194.94M	-$4.80M	$3.55B	$332.53M

Deciphera Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCPH Deciphera Pharmaceuticals	N/A	$25.59 flat	N/A	N/A	$2.21B	$174.91M	N/A	300
ABVX Abivax	3.1823 of 5 stars	$117.38 +10.5%	$137.15 +16.8%	N/A	$8.42B	N/A	N/A	61	Positive News Gap Up
PCVX Vaxcyte	2.1771 of 5 stars	$57.24 -0.1%	$86.00 +50.2%	N/A	$8.28B	N/A	N/A	160	Upcoming Earnings
NUVL Nuvalent	3.7115 of 5 stars	$100.28 +1.2%	$137.25 +36.9%	N/A	$7.79B	N/A	N/A	40	Upcoming Earnings
KRYS Krystal Biotech	3.3577 of 5 stars	$262.26 +0.9%	$326.25 +24.4%	N/A	$7.65B	$389.13M	38.29	210	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCPH) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Deciphera Pharmaceuticals (DCPH) Competitors

DCPH vs. ABVX, PCVX, NUVL, KRYS, and CYTK

How does Deciphera Pharmaceuticals compare to Abivax?

Summary

How does Deciphera Pharmaceuticals compare to Vaxcyte?

Summary

How does Deciphera Pharmaceuticals compare to Nuvalent?

Summary

How does Deciphera Pharmaceuticals compare to Krystal Biotech?

Summary

How does Deciphera Pharmaceuticals compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCPH vs. The Competition

Deciphera Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Deciphera Pharmaceuticals (DCPH) Competitors

DCPH vs. ABVX, PCVX, NUVL, KRYS, and CYTK

How does Deciphera Pharmaceuticals compare to Abivax?

Summary

How does Deciphera Pharmaceuticals compare to Vaxcyte?

Summary

How does Deciphera Pharmaceuticals compare to Nuvalent?

Summary

How does Deciphera Pharmaceuticals compare to Krystal Biotech?

Summary

How does Deciphera Pharmaceuticals compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCPH vs. The Competition

Deciphera Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools